Pfizer Inc.


Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

$36.94 -0.05 (-0.14%)

Quote Date: Jan 19, 4:11PM EST

Data delayed 15 minutes
Currency in USD

PFE News

    Pfizer confirms FDA approval for Sutent in renal cell carcinoma

    Pfizer announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. The approval was based on results from the S-TRAC trial that demonstrated a significant reduction in the risk of a disease-free survival event for patients at high risk of RCC recurrence who received SUTENT compared to placebo in the adjuvant setting. SUTENT has been a standard of care for the treatment of advanced RCC since it was approved more than a decade ago, and is now the first approved adjuvant treatment option for certain patients at high risk of recurrent RCC - the most common type of kidney cancer. The current treatment approach for RCC patients is surgery followed by observation, which is suboptimal for patients at high risk of recurrence.

    PFE11/16 17:00 EDT

    FDA expands approval of Pfizer's Sutent

    The U.S. Food and Drug Administration approved Sutent for the adjuvant treatment of adult patients who are at a high risk of kidney cancer returning after a kidney has been removed. Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back. The labeling for Sutent contains a boxed warning to alert healthcare professionals and patients about the risk of severe liver damage, which may result in liver failure or death. The FDA granted the expanded approval of Sutent to Pfizer.

    PFE11/16 16:00 EDT

    Pfizer, Novartis agree to UK price cuts for breast cancer drugs, Reuters reports

    Pfizer (PFE) and Novartis (NVS) have agreed to decrease prices on their rival breast cancer drugs Ibrance and Kisqali to allow the treatments to be used consistently in Britain's state-funded health service, Reuters reports, citing the National Institute for Health and Care Excellence. The oral drugs, which are administered in conjunction with hormonal therapies, inhibit CDK 4 and 6 proteins and have the same official list price of GBP2,950, or $3,882 for one treatment cycle. The size of the discount on the drugs are commercially confidential. [Reference Link]:Link

    PFE;NVS11/16 07:28 EDT

    Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo

    Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.

    NEOS;PFE11/14 17:58 EDT

    BMO argues for Biogen as most logical takeover target for Pfizer

    Commenting on "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal, BMO Capital analyst Alex Arfaei argued that he sees a strong strategic rationale for a merger with Biogen (BIIB). The analyst sees a deal for Bristol-Myers Squibb (BMY) as unlikely given the uncertainty associated with the latter's pipeline. PFIZER/BIOGEN MERGER: In a research note to investors this morning, BMO Capital's Arfaei noted the that there is "significant market speculation" that Pfizer is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that the company could target Bristol-Myers given Pfizer's focus on oncology and Bristol's setbacks, the analyst believes a deal for Biogen would make more sense. Pointing out that Pfizer has a "significant gap" in neurology, Arfaei says the company cannot afford to be behind in both Immuno-Oncology, or I-O, and Alzheimer's disease. In the latter area, Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) all have pivotal trials reading out in 2019-2020. Biogen's aducanumab has shown "very promising data," the pipelines are complementary, and Pfizer could probably manage Biogen's mature neurology franchise more efficiently, he contended. Further, the analyst argued that Pfizer could have an opportunity to leverage near-term volatility in Biogen's multiple sclerosis franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development. He reiterated an Outperform rating and $39 price target on Pfizer's shares. WHAT'S NOTABLE: Pfizer has announced that Albert Bourla was named COO effective January 1, 2018. Bourla has been the Group President of Pfizer's Innovative Health Business since the beginning of 2016. Under his leadership revenues for the Pfizer Innovative Health business grew 11% operationally in 2016 and in the first nine months of 2017 have grown 9% operationally. PRICE ACTION: In morning trading, shares of Pfizer are fractionally up to $35.27, while Biogen's stock is fractionally higher at $310.79. Shares of Bristol-Myers are fractionally lower to $60.71.


    Pfizer names Albert Bourla COO

    Pfizer announced that Albert Bourla has been named COO effective January 1, 2018. Bourla has been the Group President of Pfizer's Innovative Health Business since the beginning of 2016. Under his leadership revenues for the Pfizer Innovative Health business grew 11% operationally in 2016 and in the first nine months of 2017 have grown 9% operationally. Effective January 1, 2018 John Young, Group President, Pfizer Essential Health becomes Group President, Pfizer Innovative Health. Angela Hwang, Global President and General Manager for Pfizer Inflammation & Immunology will succeed John Young as Group President, Pfizer Essential Health.

    PFE11/13 09:22 EDT

    BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers

    BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.


    Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray

    Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.

    PFE11/13 06:09 EDT

    Pfizer sells 49% stake in Hisun-Pfizer Pharmaceuticals joint venture

    Pfizer and Zhejiang Hisun Pharmaceuticals announced that Pfizer has sold its 49% equity share in its joint venture, Hisun-Pfizer Pharmaceuticals Co., Ltd. to Sapphire I Holdings Limited. Hisun-Pfizer Pharmaceuticals Co., Ltd. is a joint venture formed by Pfizer and Hisun in 2012 to develop, manufacture and commercialize branded generic pharmaceutical products in China and global markets. The transfer of Pfizer's equity stake will allow both Hisun and Pfizer to focus on their core strengths. After Pfizer's equity share transfer, the joint venture will change its name but will retain its current rights to manufacture, sell and distribute all of Hisun-Pfizer Pharmaceutical's currently marketed and pipeline products in China. Pfizer will continue to support a technology transfer process to ensure that the products that had previously been licensed to Hisun-Pfizer Pharmaceuticals by Pfizer, will in the future, be manufactured locally in China. Pfizer will continue to supply certain products to the joint venture for a period of time, after closing, to facilitate a smooth transition. Pfizer and Hisun will maintain a strong and collaborative relationship, providing for the ongoing supply of high-quality generic products to patients in China through the joint venture.

    PFE11/10 12:04 EDT

    Spark Therapeutics, Pfizer amend license agreement for SPK-9001

    Spark Therapeutics (ONCE) and Pfizer (PFE) announced they have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B. Spark Therapeutics will enroll up to five additional participants in the current Phase 1/2 clinical trial who will receive SPK-9001 manufactured using an enhanced process to test its comparability to the SPK-9001 received by the first 10 participants enrolled in the ongoing trial. One of the up to five participants has already received SPK-9001 manufactured using the enhanced process. As of Oct. 23, this participant has been followed for 32 weeks post-infusion. The participant's factor IX activity level has plateaued within the range that is considered comparable to the first 10 participants, and this participant's number of prophylactic intravenous factor IX infusions has been reduced to zero. Subject to the terms of the amendment, Spark Therapeutics will receive from Pfizer an initial $10M cash payment and up to an additional $15M in potential milestone payments upon completion of certain transition activities.

    ONCE;PFE11/7 07:20 EDT

    FDA Vaccines & Related Biological Products Advisory Committee holds a meeting

    The Committee holds a meeting to discuss and make recommendations on the clinical development plan for Pfizer's investigational Staphylococcus aureus vaccine intended for pre-surgical prophylaxis in elective orthopedic surgical populations will be held at FDA Silver Spring, MD offices on November 7 at 8:30 am. [Webcast Link]:Link

    PFE11/6 15:31 EDT

    Pfizer call volume above normal and directionally bullish

    Bullish option flow detected in Pfizer with 14,164 calls trading, 2x expected, and implied vol increasing over 1 point to 14.86%. Nov-17 35.5 calls and Dec-17 36 calls are the most active options, with total volume in those strikes near 11,200 contracts. The Put/Call Ratio is 0.11. Earnings are expected on January 30th.

    PFE11/6 10:45 EDT

    American College of Rheumatology City to hold annual meeting

    Annual Meeting of ACR/ARHP 2017 is being held in San Diego on November 3-8.


    EpiPen failures cited in seven deaths this year, Bloomberg reports

    Mylan's (MYL) EpiPens, used to prevent allergic reactions that may in some cases kill, have been cited in seven deaths this year through mid-September due to the failure of the device to deploy correctly, Bloomberg reports, citing reports by patients and physicians made to the U.S. FDA. The agency has received a total of 228 reports of EpiPen or EpiPen Jr. failures during the time period and 35 hospitalizations have been linked to the medical device, which is manufactured by Pfizer's (PFE) Meridian Medical Technologies and had its price raised by Mylan to over $600 for a two-pack from roughly $50 for a single pen last year. [Reference Link]:Link

    MYL;PFE11/2 06:36 EDT

    Pfizer risk/reward remains favorable, says UBS

    UBS analyst Marc Goodman said he continues to like Pfizer's risk/reward following its Q3 results. The analyst believes the company could unlock some value with potential strategic action on its consumer business and also thinks its pipeline gets minimal credit. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.

    PFE11/1 07:35 EDT

    Pfizer expects many suitors for consumer health business, Reuters says

    Pfizer is expecting a lot of interest in its consumer health business that it plans on selling, spinning off or retaining, according to Reuters. This business did approximately $3.4B in sales in 2016 and contains popular brands like Advil. The Essential Health unit cited a supply problem causing an 11% drop in Q3 revenue. [Reference Link]:Link

    PFE10/31 13:55 EDT

    On The Fly: Top stock stories at midday

    Stocks opened in positive territory and have remained there throughout the morning. The averages have been locked in a narrow range but have cut into the losses the market experienced yesterday. The day's economic data, including the Chicago Purchasing Manger's report and Conference Board consumer confidence reading, were well ahead of expectations, helping solidify the market's move. ECONOMIC EVENTS: In the U.S., the Conference Board consumer confidence reading jumped 5.3 points to a 17-year high of 125.9 in October. The Chicago PMI, which was expected to have fallen in October from 65.2 the prior month, actually rose 1.0 point to 66.2. The 20-City Case Shiller home price index rose 0.42% to 202.87 in August. COMPANY NEWS: After CNBC's David Faber broke the news that Emerson Electric (EMR) in early October increased its takeover bid for Rockwell Automation (ROK) to $215 per share from the $200 per share it offered in August, both stocks were halted and confirmed the report. Rockwell said its board unanimously determined that each of Emerson's proposals was not in the best interest of the company or its shareowners, while Emerson added that no discussions are currently ongoing and that it "remains a disciplined acquirer and will only pursue transactions that are in the best interests of its shareholders." Following the confirmations, Rockwell shares are up 8% near midday, while Emerson shares are down about 3%... Class A shares of Under Armour (UAA) have plunged 18% after the company cuts its fiscal year revenue outlook for the second quarterly report in a row, citing operational challenges and lower demand in North America. After the report, Morgan Stanley analyst Jay Sole said Under Armour fell short of "even the lowest expectations" and he does not believe that this is necessarily the bottom for the stock... Qualcomm (QCOM) shares have fallen 7%, while Intel (INTC) shares are up 2%, after The Wall Street Journal said Apple (AAPL) is developing iPhones and iPads for next year that would drop Qualcomm's components and could use Intel as an exclusive alternate supplier... Pfizer (PFE) is down about 1% after the Dow member reported better than expected earnings and roughly in-line quarterly sales, raised its full-year profit view and narrowed its revenue outlook. MAJOR MOVERS: Among notable companies up after earnings were Mondelez (MDLZ), which advanced 6%, Kellogg (K), which gained 5% and Sony (SNE), which rose 15%. Some noteworthy losers after reporting earnings were Shopify (SHOP), which slid 11%, Archer Daniels (ADM), which fell 5% and FIS (FIS), which dipped 3%. INDEXES: Near 1 pm ET, the Dow was up 20.05, or 0.09%, to 23,368.79, the Nasdaq was up 26.33, or 0.39%, to 6,725.29, and the S&P 500 was up 3.38, or 0.13%, to 2,576.21.


    Unusually active option classes on open October 31st

    Unusual total active option classes on open include: Omega Healthcare (OHI), Plains All American (PAA), Emerson (EMR), CB&I (CBI), Mondelez (MDLZ), Mastercard (MA), Qualcomm (QCOM), Salesforce (CRM), Pfizer (PFE), and US Steel (X).


    On The Fly: Pre-market Movers

    UP AFTER EARNINGS: Mastercard (MA), up 1.9%... Pfizer (PFE), up marginally... Aetna (AET), up just under 1%... IPG Photonics (IPGP), up 4.4%... Kellogg (K), up 6.1%... Mosaic (MOS), up 5.4%... Incyte (INCY), up 2.9%. ALSO HIGHER: Rockwell Automation (ROK), up 12.1% after CNBC's David Faber reported Rockwell rejected $215 per share takeover bid from Emerson Electric (EMR) in early October. Emerson is up marginally... Intel (INTC) is up 1.8% while Apple (AAPL) is up marginally following a Wall Street Journal report that the company is developing iPhones and iPads that would only use Intel chips as the electronics giant is looking to stop using Qualcomm (QCOM) components in their devices. DOWN AFTER EARNINGS: Under Armour (UAA, UA), down 15.6% and 13.1%, respectively... Archer Daniels (ADM), down 2.1%... Cummins (CMI), down 1.5%... Carlyle Group (CG), down just under 1%... AK Steel (AKS), down 4.7%... Lumber Liquidators (LL), down 5.3%. ALSO LOWER: Nike (NKE), down 1.4% after Under Armour reported quarterly results... Qualcomm is down 3.8% following the Wall Street Journal report about Apple using Intel chips in their devices.


    Unusual call flow in option market yesterday

    Notable call activity was cited Monday in Apple (AAPL), Facebook (FB), AT&T (T), General Motors (GM), Teva (TEVA), Applied Materials (AMAT), Pfizer (PFE), EBay (EBAY), Skyworks (SWKS), and Zions Bancorp (ZION).


    Pfizer CEO says 'reported solid third-quarter results'

    Ian Read, Chairman and CEO, stated, "We reported solid third-quarter 2017 financial results and raised the midpoint of the range for our 2017 Adjusted diluted EPS guidance. Innovative Health revenues grew 11% operationally, primarily driven by the performance of our key growth drivers, notably Ibrance, Eliquis, Xtandi and Xeljanz, all of which are products that are early in their patent-protected lifecycle in attractive therapeutic areas. While Essential Health revenues remained challenged primarily due to continued headwinds from products that recently lost marketing exclusivity and product supply, we had solid operational growth in emerging markets and in biosimilars. Looking ahead, we are encouraged by the convergence of two positive trends: an expected decline in the unfavorable revenue impact associated with product losses of exclusivity and the beginning of an expected multi-year wave of potential new product launches and product line extensions driven by our pipeline. We believe that the convergence of these trends, coupled with anticipated continued strong growth from the aforementioned innovative products, positions the Company for long-term success." Frank D'Amelio, Executive Vice President, Business Operations and CFO, stated, "Overall, I am pleased with our third-quarter 2017 financial results, including 2% operational revenue growth after excluding the net impact of acquisitions and divestitures completed in 2016 and the first nine months of 2017. As a result of our strong performance to date in 2017, we narrowed the ranges for certain 2017 financial guidance components, including a $0.03 increase to the midpoint of our range for Adjusted diluted EPS to a range of $2.58 to $2.62. The midpoint of our new guidance range for Adjusted diluted EPS implies 8% growth compared with last year. Finally, earlier this month, we announced that we are reviewing strategic alternatives for our Consumer Healthcare business."

    PFE10/31 07:14 EDT

    Pfizer narrows FY17 revenue view to $52.4B-$53.1B from $52B-$54B

    FY17 consensus $52.72B.

    PFE10/31 06:47 EDT

    Pfizer raises FY17 adjusted EPS view to $2.58-$2.62, consensus $2.56

    Prior view was $2.54-$2.60.

    PFE10/31 06:46 EDT

    Pfizer reports Q3 adjusted EPS 67c, consensus 65c

    Reports Q3 revenue $13.2B, consensus $13.17B.

    PFE10/31 06:45 EDT

    Notable companies reporting before tomorrow's open

    Notable companies reporting before tomorrow's open, with earnings consensus, include Pfizer (PFE), consensus 65c... Mastercard (MA), consensus $1.23... Aetna (AET), consensus $2.08... Ecolab (ECL), consensus $1.36... Fidelity National Information Services (FIS), consensus $1.06... Cummins (CMI), consensus $2.46... HCA Healthcare (HCA), consensus $1.93... Incyte (INCY), consensus 5c... Archer Daniels (ADM), consensus 56c... Kellogg (K), consensus 94c... IPG Photonics (IPGP), consensus $1.82... WellCare Health Plans (WCG), consensus $1.91... Carlyle Group (CG), consensus 51c... Mosaic (MOS), consensus 18c... Under Armour (UAA), consensus 19c... AK Steel (AKS), consensus 4c... Lumber Liquidators (LL), consensus 2c.


    Pfizer call volume above normal and directionally bullish

    Bullish option flow detected in Pfizer with 23,782 calls trading, 2x expected, and implied vol increasing almost 2 points to 17.28%. Nov-17 35.5 calls and Jan-18 32 puts are the most active options, with total volume in those strikes near 13,700 contracts. The Put/Call Ratio is 0.32. Earnings are expected on October 31st.

    PFE10/30 11:45 EDT

    Bristol-Myers rises after Merck pulls cancer drug combo filing in Europe

    Shares of Bristol-Myers Squibb (BMY) are on the rise after competitor Merck (MRK) announced it is withdrawing its European application for a combination regimen featuring Keytruda, the company's cancer immunotherapy drug. Following the news, SunTrust analyst John Boris upgraded the former's stock to Buy as he believes Merck's KN-189 data delay and withdrawal of its European application for Keytruda improves Bristol-Myers' competitive position. Meanwhile, several Wall Street analysts downgraded Merck to hold-equivalent ratings. EUROPEAN WITHDRAWAL: Merck has announced that it has withdrawn its European application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer. The application was based on findings from KEYNOTE-021, Cohort G. Merck said it is confident in the clinical data from this "rigorously conducted trial," which demonstrated significant improvements in overall response rate and progression-free survival for the Keytruda combination regimen compared to chemotherapy alone. BUY BRISTOL-MYERS: In a research note to investors this morning, SunTrust's Boris upgraded Bristol-Myers to Buy from Hold and raised his price target on the shares to $75 from $55, saying Merck's KN-189 data delay to 2019 and withdrawal of its EU first-line NSCLC filing improves Bristol's competitive position. Boris noted he models an additional $2B in 2021 revenue as a result, adding that he has increased confidence in the Opdivo + Yervoy arm of the Checkmate-227 trial expected in 2018 to generate overall survival benefits. Additionally, the analyst told investors that he views Bristol-Myers as an attractive strategic asset that could make sense to get a potential bid from Pfizer (PFE). However, such a scenario depends on macro factors such as tax reform and/or repatriation and "binary events" in the marketplace, including the read-out from the company's 227 trial. MERCK DOWNGRADES: Following the Keytruda news, Barclays analyst Geoff Meacham downgraded Merck to Equal Weight from Overweight based on diminished upside potential from Keytruda, which is the company's biggest value driver. With the formal withdrawal of the EU filing in front-line NSCLC and delays to the Phase 3 KN-189 trial from adding overall survival as a co-primary endpoint, the analyst argued that he sees less upside potential for Keytruda sales in lung cancer. While he does not think this means I/O rivals will "leapfrog" Merck, Meacham pointed out that both Bristol-Myers and Roche (RHHBY) could have front-line NSCLC data in late 2017/early 2018 that could further weigh on sentiment. He was not the only analyst cutting Merck's rating this morning. Morgan Stanley analyst David Risinger also downgraded the stock to Equal Weight from Overweight on similar reasons. The analyst noted that the negative Keytruda updates caused him to lower projections, while adding that Keytruda's lung cancer readout delay limits sales and exposes Merck to competitive threats. Meanwhile, SunTrust analyst John Boris downgraded Merck to Hold from Buy and lowered his price target on the shares to $54 from $73 to reflect lower Keytruda sales. The analyst also argued that Merck's HCV/HIV and Zostavax vaccine franchises face significant competitive headwinds, anticipating an added headwind to the bottom line as the company is unable to reduce its R&D or SG&A expenses to preserve its immuno-oncology position. PRICE ACTION: In morning trading, shares of Bristol-Myers have gained over 2% to $61.16, while Merck's stock has dropped almost 5% to $55.41.

    BMY;MRK;PFE;RHHBY10/30 11:13 EDT

    Cardiovascular Research Foundation to hold a conference

    Transcatheter Cardiovascular Therapeutics Conference: TCT 2017 is being held in Denver, Colorado on October 29-November 2.


    American College of Chest Physicians to hold annual meeting

    CHEST Annual Meeting 2017 is being held in Toronto, Canada on October 28-November 1.


    Switching data in patients with Crohn's supports use of Pfizer INFLECTRA

    New data show that switching patients with Crohn's disease, or CD, to INFLECTRA from REMICADE led to comparable efficacy, safety and tolerability to treatment with REMICADE over a 24-week period. The full 54-week results of the randomized controlled trial comparing INFLECTRA and REMICADE in biologic-naive patients with active CD support the long-term effectiveness of treatment with INFLECTRA. The results also show that INFLECTRA was well-tolerated, with a similar safety profile to REMICADE. Pfizer and Celltrion Healthcare jointly announced the secondary outcomes from the phase III trial of INFLECTRA in CD at the 25th United European Gastroenterology Week. The study previously reported its primary endpoint at six weeks, demonstrating non-inferiority of INFLECTRA compared to REMICADE in the treatment of CD. More than 50 real-world studies in IBD have been conducted with INFLECTRA, evaluating over 7,500 IBD patients in real-world settings. There is an important and growing body of evidence for the switching of stable REMICADE patients to INFLECTRA. Clinical studies supporting this switch include NOR-SWITCH,15 BIO-SWITCH,16 PROSIT-BIO3 and now CT-P13 3.4.

    PFE10/29 19:11 EDT

    Pfizer to begin consumer health sale in November, Reuters reports

    Pfizer (PFE) is expecting to begin an auction process for its consumer healthcare business, which could potentially bring in over $15B, Reuters reports, citing sources close to the matter. Possible suitors include GlaxoSmithKline (GSK), Reckitt Benckiser (RBGLY), Procter & Gamble (PG), Sanofi (SNY), Johnson & Johnson (JNJ), and Nestle (NSRGY) and the drugmaker has already held preliminary discussions with interested parties including Reckitt. [Reference Link]:Link


    North American Spine Society to hold a conference

    NASS 2017 is being held in Orlando, FL on October 25-28.


    Worldwide Business Research to hold a summit

    BioNetwork Partnering Summit is being held in Laguna Nigel, CA on October 23-25.


    American Society of Anesthesiology to hold annual meeting

    Anesthesiology 2017 Annual Meeting is being held in Boston on October 21-25.


    World Congress to hold a summit

    5th Annual Patient Advocacy Summit is being held in Arlington, VA on October 23-24.


    The Food & Drug Law Institute to hold a symposium

    Food and Drug Law Journal Symposium 2017 discusses whether the FDA should encourage smokers to move to vaping, how labeling food products is perceived and h ow the agency can address the opioid epidemic and is being held in Washington, D.C. on October 20.

    PFE10/20 07:17 EDT

    Pfizer reports 5.4% passive stake in Rhythm Pharmaceuticals

    PFE;RYTM10/18 15:43 EDT

    Drug Information Association to hold a conference

    Metrics in Patient-Centered Drug Development Conference is being held in Rockville, MD on October 18-19.


    European Society of Gene & Cell Therapy will hold a conference

    25th Anniversary Congress of the ESGCT will be held in Berlin, Germany on October 17-20.


    Trump calls prescription drug prices 'out of control,' CBS reports

    CBS News White House Correspondent Mark Knoller reported that in remarks to the Cabinet, President Trump said that "prescription drug prices are out of control." "Drug companies quite frankly are getting away with murder," added Trump, according to Knoller. Some of the largest publicly traded pharmaceutical companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).


    International Association for Study of Lung Cancer holds a conference

    18th World Conference on Lung Cancer is being held in Yokohama, Japan on October 15-18.


    Pfizer announces Phase 2 Study results of ALK-inhibitor lorlatinib

    Pfizer announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer, including those who were heavily pretreated. Further, side effects were generally manageable and primarily mild to moderate in severity. The results were presented by Professor Benjamin Solomon, lead investigator and medical oncologist at Peter MacCallum Cancer Centre, Melbourne, Australia, today during an oral session at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer in Yokohama, Japan. Pfizer will also present data from several other lung cancer clinical programs. The Phase 2 study examined the antitumor activity and safety of lorlatinib in 275 patients with or without asymptomatic, untreated or treated brain metastases. Patients were enrolled in six cohorts based on biomarker and prior therapy. The primary endpoints were objective response rate and intracranial ORR confirmed by independent central review. Results by clinically relevant groups showed: ALK-positive treatment-naive: ORR was 90% and IC-ORR was 75%. ALK-positive previously treated with crizotinib with or without chemotherapy: ORR was 69% and IC-ORR was 68%.ALK-positive previously treated with a non-crizotinib ALK inhibitor with or without chemotherapy: ORR was 33% and IC-ORR was 42%. ALK-positive previously treated with two or three prior ALK inhibitors with or without chemotherapy: ORR was 39% and IC-ORR 48%. ROS1-positive regardless of prior treatment: ORR was 36% and IC-ORR was 56%.Lorlatinib was generally tolerable. Most adverse events were mild to moderate and were managed by dose reductions or delay or with standard medical therapy. There were no treatment-related deaths and a low rate of discontinuation due to drug-related adverse events. The most common adverse events were: hypercholesterolemia, hypertriglyceridemia, edema, peripheral neuropathy, weight increase, cognitive effects, mood effects, fatigue, diarrhea, arthralgia, and increased AST. The Phase 2 data will form the basis of discussions with global regulatory authorities, including the U.S. Food and Drug Administration. On April 26, 2017, the FDA granted Breakthrough Therapy designation for lorlatinib for the treatment of patients with ALK-positive metastatic NSCLC previously treated with one or more ALK inhibitors.

    PFE10/16 07:08 EDT

    Pfizer announcement creates M&A opportunity for Prestige Brands,says DA Davidson

    DA Davidson analyst Linda Bolton Weiser says Pfizer's (PFE) announcement that is is reviewing strategic alternatives for its $3.4B OTC drug business could create M&A opportunity down the road for Prestige Brands (PBH). If sold, the price tag could be over $10B, clearly too big for Prestige Brands, but the buyer could later sell some or all of the small brands, the analyst contended. With Prestige Brands continuing to de-lever its balance sheet and approaching the one year anniversary in January of its last deal, Weiser believes the company could within months announce an accretive acquisition. She reiterates a Buy rating and $79 price target on Prestige Brands shares.

    PBH;PFE10/12 09:33 EDT

    Pfizer reports FDA approval of Lyrica CR ER tablets CV

    Pfizer announced that the FDA has approved LYRICA CR extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy and the management of postherpetic neuralgia. LYRICA CR did not receive approval for the management of fibromyalgia. The efficacy and safety of LYRICA CR in PHN was established in a randomized placebo-controlled clinical trial conducted in a total of 801 patients with PHN who entered single-blind treatment with LYRICA CR. As both pDPN and PHN are peripheral neuropathic pain conditions, the PHN data was supportive of both the pDPN and PHN indications. The randomized trial included a six-week single-blind, dose optimization phase followed by a 13-week double-blind phase. In the PHN study, 73.6 percent of patients in the LYRICA CR group achieved at least 50 percent improvement in pain intensity compared with 54.6 percent in the placebo group. The most common adverse reactions reported with LYRICA CR were dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth and weight gain.

    PFE10/12 08:06 EDT

    Pfizer sale of consumer unit most likely option, says Deutsche Bank

    Deutsche Bank analyst Gregg Gilbert believes a sale of Pfizer's Consumer Healthcare unit is the most likely outcome of the company's strategic review process. The analyst says he wouldn't be surprised if Pfizer has already received indications of interest in the business. A sale of the unit could be 3%-4% accretive depending on the price and assuming the company uses the proceeds to repurchase shares in order to offset dilution, Gilbert tells investors in a research note. He likes that management continues to explore strategic alternatives to increase shareholder value and keeps a Buy rating on Pfizer with a $38 price target.

    PFE10/11 07:47 EDT

    Glaxo could be good fit for Pfizer's consumer unit, Breakingviews says

    GlaxoSmithKline (GSK) could be a good fit for Pfizer's (PFE) consumer goods division, which it is considering selling or spinning off, Breakingviews says. GlaxoSmithKline's new boss, Emma Walmsley, has pledged to focus on her the company's drugs, including its HIV and asthma medications, but Breakingviews suggests folding Pfizer's consumer unit into Glaxo's joint venture with Novartis (NVS). Ideally, Breakingviews says Glaxo would buy out Novartis before doing any other deals. [Reference Link]:Link

    GSK;PFE;NVS10/11 06:04 EDT

    On The Fly: Top stock stories at midday

    Stocks opened in positive territory and saw their highs a short time after the open. The market has mostly moved in a narrow range, though it has turned mixed, with Wal-Mart (WMT) helping to keep the Dow in the green while the Nasdaq has fallen into negative ground. Oil prices began the day with gains and have stayed strong, with WTI now approaching the $51 a barrel level. ECONOMIC EVENTS: In the U.S., no economic data of note was reported. In Europe, German exports and imports both were reported to have grown more than expected in August. In Asia, the head of China's Statistics Bureau said, according to Reuters, that China will have no problem meeting, and may even beat, its 6.5% economic growth target for this year. COMPANY NEWS: Shares of Wal-Mart have advanced almost 5% while the company hosted its investor day meeting. The retail giant backed its FY18 profit forecast, said it sees its FY19 earnings to grow 5% on top of that and announced plans to buy back $20B of its shares over a two-year period... Offsetting some of Wal-Mart's positive impact on the Dow was a slide in Procter & Gamble (PG), which fell 1.5% after the company announced that Trian's Nelson Peltz failed to win a seat on its board. The activist investor, however, disputed that assertion, calling today's vote "too close to call" yet... Honeywell (HON) announced the results of its portfolio review, including plans to spin off its Turbochargers and Homes & Global Distribution businesses into separate companies and keep its other units. Stifel analyst Robert McCarthy said this was a "safe, predictable portfolio move" and a modest positive, while Citi analyst Andrew Kaplowitz said investors may have wanted to see more given the "overhyped buildup" into the news. In other portfolio news that was not as widely anticipated, Pfizer announced that it is reviewing strategic alternatives, including a full or partial separation through a spinoff, sale or other transaction, for its Consumer Healthcare business. MAJOR MOVERS: Among the notable gainers was MannKind (MNKD), which rose 27% after H.C. Wainwright initiated coverage of the stock with a Buy rating and $7 target, saying the "game-changing" new label approved last week will allow Afrezza to gain a footing in the "very large insulin space." Also higher was Nutanix (NTNX), which gained 11% after William Blair analyst Jason Ader told investors that his conviction in the company is "rising to new levels" following his channel discussions. Among the noteworthy losers was Symantec (SYMC), which dropped 3.5% after Morgan Stanley downgraded the stock to Equal Weight, becoming at least the third firm in the last two days to lower its rating on the shares. INDEXES: Near midday, the Dow was up 22.26, or 0.1%, to 22,783.33, the Nasdaq was down 15.59, or 0.24%, to 6,564.14, and the S&P 500 was nearly unchanged at 2,545.38.


    On The Fly: Pre-market Movers

    HIGHER: Honeywell (HON), up marginally after announcing portfolio changes providing preliminary third quarter results, and narrowing fiscal 2017 guidance... Wal-Mart (WMT), up 2% after backing fiscal 2018 guidance and announcing a new $20B share buyback program... Pfizer (PFE), up 1% after announcing that it is reviewing strategic alternatives for its Consumer Healthcare business... Express Scripts (ESRX), up 1.3% after announcing it will acquire eviCore healthcare for $3.6B. LOWER: Ionis Pharmaceuticals (IONS), down 1% after Akcea Therapeutics UK announced that volanesorsen has been granted a Promising Innovative Medicine Designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome... Eli Lilly (LLY), down 2.5% after its Phase 3 JUNIPER study evaluating Verzenio, a cyclin-dependent kinase, or CDK,4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer, or NSCLC, did not meet its primary endpoint of overall survival... AIG (AIG), down 2% after it said it estimates $2.9B-$3.1B in pre-tax catastrophe losses in the third quarter.


    Pfizer reviewing strategic alternatives for Consumer Healthcare Business

    Pfizer announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. This announcement is part of Pfizer's continuing efforts to allocate resources and capital to best serve patients and maximize value for its shareholders. Pfizer Consumer Healthcare is one of the largest OTC health care products businesses in the world with 2016 revenues of approximately $3.4B, operating in more than 90 countries globally. Consumer Healthcare markets two of the ten top selling consumer healthcare brands globally - Centrum and Advil. In addition, the business has ten brands that each exceeded $100M in 2016 sales, and several local brands that are top-ranked in their respective markets. Pfizer has engaged Centerview Partners LLC, Guggenheim Securities LLC and Morgan Stanley & Co. LLC as financial advisors for the strategic review process. Pfizer expects that any decision regarding strategic alternatives for Pfizer Consumer Healthcare would be made during 2018. The company does not plan to make any further statements about the strategic review process until a decision has been reached or upon the completion of the strategic review.

    PFE10/10 06:46 EDT

    Pfizer launches programs to support cancer patients

    Pfizer unveiled enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer Oncology medicines that offers dedicated social workers called 'Care Champions' to help navigate the complexities that accompany treatment, such as identifying resources to help find emotional support, and workplace transition, transportation and financial assistance. Pfizer also launched This is Living with Cancer, a program that provides tools and resources to support those who have been affected by cancer, including a mobile app, LivingWith, designed to help manage some of the daily challenges faced by people living with cancer.

    PFE10/5 08:09 EDT

Data At A Glance (Annual)

  TTM 2017201620152014
Revenue (Millions) $52,470$38,843$52,824$48,851$49,605
Cost of Revenue Expense (Millions) $11,198$7,980$12,328$9,647$9,577
Current Assets (Millions) $40,291$40,291$38,949$43,804$57,702
Current Debt (Millions) $9,448$9,448$10,688$10,160$5,141
Current Liabilities (Millions) $28,217$28,217$31,115$29,399$21,631
Deferred Taxes (Millions) -$79-$79$635$147-$449
EBITDA (Millions) $19,609$16,987$15,294$14,734$19,802
Essential Revenue (Millions) $22,204$10,590$23,628$21,982$25,149
Financing Cash Flow (Millions) -$11,878-$9,650-$8,921-$10,233-$9,986
Free Cash Flow (Millions) $13,487$8,284$13,902$13,016$15,300
Goodwill (Millions) $56,078$56,078$54,449$48,242$42,069
Gross Profit (Millions) $10,321$10,321$10,410$10,637$10,416
Interest Expense (Millions) $1,238$941$1,186$613$664
Investing Cash Flow (Millions) -$3,069$38-$7,811-$2,980-$5,654
Net Income (Millions) $9,809$9,034$7,215$6,960$9,135
Net Interest Income (Millions) -$0-$0-$0-$0-$0
Operating Income (Millions) $12,333$11,556$8,352$8,258$9,119
Premarian Revenue (Millions) $976$711$1,016$1,018$1,076
Research & Development Expense (Millions) $7,859$5,347$7,872$7,681$7,153
Selling, General & Administrative Expense (Millions) $14,656$10,233$14,838$14,808$14,097
Selling, Informational & Administrative Expense (Millions) $14,656$10,233$14,838$14,782$13,721
Share Count (Millions) 5,9615,9616,0706,1756,291
Total Assets (Millions) $172,151$172,151$171,615$167,460$169,274
Total Debt (Millions) $43,951$43,951$42,086$38,978$36,682
Total Equity (Millions) $60,770$60,770$59,544$64,720$71,301
Total Liabilities (Millions) $111,381$111,381$112,071$102,740$97,973
Emerging Markets Chantix/Champix Revenue (Millions) $39$30$33$43$37
Emerging Markets Internal Medicine Revenue (Millions) $555$425$494$479$455
Emerging Markets Lyrica IH Revenue (Millions) $212$159$217$276$90
Emerging Markets PFIZER INNOVATIVE Revenue (Millions) $4,102$3,126$3,724$4,020$1,104
Emerging Markets All Other Biosimilars Revenue (Millions) $19$14$16$4--
Emerging Markets All other Internal Medicine Revenue (Millions) $155$90$211$136$28
Emerging Markets All other LEP Revenue (Millions) $1,485$1,137$1,395$1,704$434
Emerging Markets All other Oncology Revenue (Millions) $7$5$10$10$3
Emerging Markets All other Peri-LOE Products Revenue (Millions) $68$50$72$88$32
Emerging Markets All other Rare Disease Revenue (Millions) $48$46$23$8$9
Emerging Markets All other SIP Revenue (Millions) $696$524$660$511$167
Emerging Markets All other Vaccines Revenue (Millions) $30$26$19$5$3
Emerging Markets Alliance revenues Revenue (Millions) $143$138$27$11$9
Emerging Markets Benefix Revenue (Millions) $58$41$47$43$34
Emerging Markets Biosimilars Revenue (Millions) $43$34$30$7--
Emerging Markets Bosulif Revenue (Millions) $3$3------
Emerging Markets Celebrex Revenue (Millions) $301$228$303$350$377
Emerging Markets Consumer Healthcare Revenue (Millions) $862$658$802$909$250
Emerging Markets Effexor Revenue (Millions) $78$58$79$91$96
Emerging Markets Enbrel (Outside Canada) Revenue (Millions) $647$472$632$790$861
Emerging Markets Fragmin Revenue (Millions) $54$41$52$54$66
Emerging Markets FSME/IMMUN-TicoVac Revenue (Millions) $16$15$18$16--
Emerging Markets Genotropin Revenue (Millions) $92$70$87$93$109
Emerging Markets Ibrance Revenue (Millions) $112$95$43$4--
Emerging Markets Inflammation & Immunology (I&I) Revenue (Millions) $713$525$675$812$239
Emerging Markets Inflectra/Remsima Revenue (Millions) $24$20$14$3--
Emerging Markets Inlyta Revenue (Millions) $41$30$43$33$22
Emerging Markets Legacy Established Products (LEP) Revenue (Millions) $3,970$2,959$3,913$4,440$1,302
Emerging Markets Lipitor Revenue (Millions) $1,213$923$1,157$1,236$1,203
Emerging Markets Lyrica EH Revenue (Millions) $108$80$109$136$48
Emerging Markets Medrol Revenue (Millions) $92$69$90$101$134
Emerging Markets Norvasc Revenue (Millions) $619$455$622$616$613
Emerging Markets Oncology Revenue (Millions) $556$443$440$398$106
Emerging Markets Peri-LOE Products Revenue (Millions) $1,302$961$1,289$1,471$419
Emerging Markets Pfizer CentreOne Revenue (Millions) $35$24$55$58-$50
Emerging Markets PFIZER ESSENTIAL HEALTH Revenue (Millions) $6,826$5,096$6,704$7,113$2,051
Emerging Markets Precedex Revenue (Millions) $37$37------
Emerging Markets Premarin Family Revenue (Millions) $27$19$29$33$41
Emerging Markets Prevnar/Prevenar 13 Revenue (Millions) $1,058$800$1,011$1,139$1,049
Emerging Markets Pristiq Revenue (Millions) $75$55$60$58$62
Emerging Markets Rare Disease Revenue (Millions) $311$234$268$263$85
Emerging Markets Refacto AF/Xyntha Revenue (Millions) $87$65$65$52$54
Emerging Markets Relpax Revenue (Millions) $16$12$16$17$19
Emerging Markets Revatio Revenue (Millions) $35$26$32$32$31
Emerging Markets Somavert Revenue (Millions) $15$11$14$14$15
Emerging Markets Sterile Injectable Pharmaceuticals (SIP) Revenue (Millions) $1,432$1,098$1,315$1,114$330
Emerging Markets Sulperazon Revenue (Millions) $426$337$383$323$333
Emerging Markets Sutent Revenue (Millions) $256$198$243$270$273
Emerging Markets Total Lyrica Revenue (Millions) $321$239$326$411$484
Emerging Markets Total Viagra Revenue (Millions) $298$225$294$313$343
Emerging Markets Toviaz Revenue (Millions) $10$8$11$12$13
Emerging Markets Tygacil Revenue (Millions) $128$92$119$124$130
Emerging Markets Vaccines Revenue (Millions) $1,103$839$1,046$1,160$295
Emerging Markets Vfend Revenue (Millions) $243$173$244$267$274
Emerging Markets Viagra EH Revenue (Millions) $298$225$294$313$88
Emerging Markets Xalatan/Xalacom Revenue (Millions) $102$75$110$122$148
Emerging Markets Xalkori Revenue (Millions) $125$100$100$79$67
Emerging Markets Xanax/Xanax XR Revenue (Millions) $73$54$69$75$82
Emerging Markets Xeljanz Revenue (Millions) $66$52$43$22$6
Emerging Markets Zithromax/Zmax Revenue (Millions) $170$131$164$168$173
Emerging Markets Zoloft Revenue (Millions) $125$95$118$124$129
Emerging Markets Zyvox Revenue (Millions) $175$125$177$228$212
Europe All Other Biosimilars Revenue (Millions) $91$67$133$28--
Europe All other I&I Revenue (Millions) -$13-$12-$9----
Europe All other Internal Medicine Revenue (Millions) $19$4$55-$129-$2
Europe All other LEP Revenue (Millions) $863$657$855$815$279
Europe All other Oncology Revenue (Millions) $14$6$33$28$6
Europe All other Peri-LOE Products Revenue (Millions) $60$42$85$141$62
Europe All other Rare Disease Revenue (Millions) $94$78$63$57$33
Europe All other SIP Revenue (Millions) $357$260$383$269$78
Europe All other Vaccines Revenue (Millions) $159$109$157$91$26
Europe BeneFIX Revenue (Millions) $200$146$243$263$282
Europe Biosimilars Revenue (Millions) $324$249$277$55--
Europe BMP2 Revenue (Millions) -$0-$0------
Europe Bosulif Revenue (Millions) $20$20------
Europe Celebrex Revenue (Millions) $28$21$31$45$137
Europe CentreOne Revenue (Millions) $117$81$160$182$39
Europe Chantix/Champix Revenue (Millions) $76$55$78$80$142
Europe Consumer Healthcare Revenue (Millions) $408$300$410$414$126
Europe Effexor Revenue (Millions) $58$43$61$71$92
Europe Eliquis Alliance Revenue (Millions) $546$435$379$224$33
Europe Enbrel Revenue (Millions) $1,474$1,053$1,852$2,130$2,511
Europe Essential Health Revenue (Millions) $3,400$2,444$4,014$4,443$1,462
Europe Fragmin Revenue (Millions) $145$106$162$179$204
Europe FSME/IMMUN-TicoVac Revenue (Millions) $115$104$100$78--
Europe Genotropin Revenue (Millions) $175$129$186$205$251
Europe Ibrance Revenue (Millions) $255$245$21$1--
Europe Inflammation & Immunology (I&I) Revenue (Millions) $1,488$1,062$1,862$2,142$647
Europe Inflectra/Remsima Revenue (Millions) $233$182$154$27--
Europe Inlyta Revenue (Millions) $79$54$103$109$107
Europe Innovative Revenue (Millions) $5,233$3,865$5,314$5,271$1,575
Europe Internal Medicine Revenue (Millions) $705$543$578$248--
Europe Legacy Established Products (LEP) Revenue (Millions) $1,479$1,069$1,562$1,633$547
Europe Lipitor Revenue (Millions) $193$129$202$207$268
Europe Medrol Revenue (Millions) $49$37$51$57$88
Europe Norvasc Revenue (Millions) $64$48$68$75$97
Europe Oncology Revenue (Millions) $862$696$649$633$174
Europe Peri-LOE Products Revenue (Millions) $842$586$1,295$1,991$749
Europe Premarin family Revenue (Millions) $4$3$4$8$8
Europe Prevnar/Prevenar 13 Revenue (Millions) $625$416$626$655$754
Europe Pristiq Revenue (Millions) $26$20$22$18$13
Europe Rare Disease Revenue (Millions) $896$660$959$1,010$312
Europe Refacto AF/Xyntha Revenue (Millions) $296$217$314$321$385
Europe Relpax Revenue (Millions) $33$24$37$62$73
Europe Revatio Revenue (Millions) $79$53$119$128$148
Europe Somavert Revenue (Millions) $122$91$122$121$137
Europe Sterile Injectable Pharmaceuticals (SIP) Revenue (Millions) $625$459$665$568$167
Europe Sutent Revenue (Millions) $322$239$338$366$416
Europe Total Alliance Revenue (Millions) $523$411$382$250$139
Europe Total Lyrica Revenue (Millions) $499$349$692$1,047$1,634
Europe Total Viagra Revenue (Millions) $46$34$50$56$86
Europe Toviaz Revenue (Millions) $63$48$65$72$91
Europe Tygacil Revenue (Millions) $75$57$70$64$74
Europe Vaccines Revenue (Millions) $872$603$854$824$274
Europe Vfend Revenue (Millions) $69$43$191$254$301
Europe Xalatan/Xalacom Revenue (Millions) $65$47$73$91$127
Europe Xalkori Revenue (Millions) $170$131$154$129$113
Europe Xanax/Xanax XR Revenue (Millions) $84$61$85$85$102
Europe Xeljanz Revenue (Millions) $27$21$20$12$6
Europe Zithromax/Zmax Revenue (Millions) $43$32$43$43$55
Europe Zoloft Revenue (Millions) $35$26$34$33$54
Europe Zyvox Revenue (Millions) $34$24$101$300$341
Global Innovative Revenue (Millions) $30,930$23,204$29,196$26,757$24,252
Global Operating Expense (Millions) $33,159$23,206$34,216$30,997$30,007
International All Other Biosimilars Revenue (Millions) $112$82$110$33--
International All other I&I Revenue (Millions) $53$38$52$64$18
International All other Internal Medicine Revenue (Millions) $231$122$375$98$18
International All other LEP Revenue (Millions) $3,306$2,527$3,162$2,776$978
International All other Oncology Revenue (Millions) $44$24$76$56$12
International All other Peri-LOE Products Revenue (Millions) $198$143$234$326$127
International All other Rare Disease Revenue (Millions) $193$164$126$91$18
International All other SIP Revenue (Millions) $1,408$1,019$1,469$1,008$297
International All other Vaccines Revenue (Millions) $201$145$182$98$32
International Benefix Revenue (Millions) $360$262$410$428$457
International Biosimilars Revenue (Millions) $381$293$315$63--
International BMP2 Revenue (Millions) -$0-$0------
International Bosulif Revenue (Millions) $38$38------
International Celebrex Revenue (Millions) $604$447$618$686$964
International CentreOne Revenue (Millions) $163$117$240$278$240
International Chantix/Champix Revenue (Millions) $248$185$245$245$269
International Consumer Healthcare Revenue (Millions) $1,572$1,183$1,490$1,597$1,749
International Effexor Revenue (Millions) $205$154$191$194$234
International Enbrel Revenue (Millions) $2,526$1,818$2,908$3,332$3,850
International EpiPen Revenue (Millions) $71$55$55$66$54
International Essential Health Revenue (Millions) $13,391$6,538$14,066$14,836$4,514
International Fragmin Revenue (Millions) $277$206$288$312$358
International FSME/IMMUN-TicoVac Revenue (Millions) $133$121$102$95-$0
International Genotropin Revenue (Millions) $428$319$437$454$539
International Ibrance Revenue (Millions) $392$362$68$4--
International Inflammation & Immunology (I&I) Revenue (Millions) $2,751$1,988$3,083$3,450$1,031
International Inflectra/Remsima Revenue (Millions) $268$210$202$30--
International Inlyta Revenue (Millions) $221$161$239$225$222
International Innovative Revenue (Millions) $12,757$9,496$12,424$12,311$3,543
International Internal Medicine Revenue (Millions) $2,688$2,006$2,482$1,907$2,025
International Legacy Established Products (LEP) Revenue (Millions) $7,371$5,443$7,435$8,170$2,486
International Lipitor Revenue (Millions) $1,628$1,215$1,593$1,700$1,820
International Lyrica EH Revenue (Millions) $607$429$801$1,184$482
International Lyrica IH Revenue (Millions) $1,055$780$1,026$993$289
International Medicine Alliance Revenue (Millions) $956$772$643$384$68
International Medrol Revenue (Millions) $163$121$166$182$254
International Norvasc Revenue (Millions) $895$656$923$956$1,073
International Oncology Revenue (Millions) $1,746$1,384$1,396$1,295$356
International Peri-LOE Products Revenue (Millions) $2,805$2,022$3,289$4,227$1,442
International Precedex Revenue (Millions) $80$80------
International Premarin Family Revenue (Millions) $57$41$60$67$84
International Prevnar/Prevenar 13 Revenue (Millions) $2,096$1,515$2,074$2,220$2,310
International Pristiq Revenue (Millions) $170$125$154$163$184
International Rare Disease Revenue (Millions) $1,597$1,182$1,628$1,652$471
International Refacto AF/Xyntha Revenue (Millions) $438$322$432$415$494
International Relpax Revenue (Millions) $92$67$97$118$137
International Revatio Revenue (Millions) $147$102$187$196$225
International Somavert Revenue (Millions) $155$115$155$151$173
International Sterile Injectable Pharmaceuticals (SIP) Revenue (Millions) $2,576$1,926$2,535$2,034$586
International Sulperazon Revenue (Millions) $439$346$396$339$355
International Sutent Revenue (Millions) $701$527$705$751$821
International Total Alliance revenues Revenue (Millions) $810$625$631$424$264
International Total Lyrica Revenue (Millions) $1,662$1,208$1,827$2,175$2,853
International Total Viagra Revenue (Millions) $415$309$417$447$545
International Toviaz Revenue (Millions) $166$125$160$151$155
International Tygacil Revenue (Millions) $208$153$194$194$211
International Vaccines Revenue (Millions) $2,401$1,752$2,342$2,412$712
International Vfend Revenue (Millions) $422$295$558$643$719
International Viagra EH Revenue (Millions) $381$284$383$410$122
International Viagra IH Revenue (Millions) $34$25$34$36$12
International Xalatan/Xalacom Revenue (Millions) $313$228$341$377$473
International Xalkori Revenue (Millions) $350$272$310$256$243
International Xanax/Xanax XR Revenue (Millions) $175$128$174$181$210
International Xeljanz Revenue (Millions) $182$142$122$53$20
International Zithromax/Zmax Revenue (Millions) $266$198$265$269$302
International Zoloft Revenue (Millions) $234$173$243$316$369
International Zyvox Revenue (Millions) $276$196$355$603$672
Rest of World Bosulif Revenue (Millions) $17$17------
Rest of World Innovative Health Revenue (Millions) $3,422$2,505$3,387$3,019$864
Rest of Wolrd Zithromax/Zmax Revenue (Millions) $52$34$56$58$75
Rest of World All other I&I Revenue (Millions) $57$41$61$64$22
Rest of World All other Internal Medicine Revenue (Millions) $56$27$108$91$22
Rest of World All other LEP Revenue (Millions) $958$733$912$918$265
Rest of World All other Oncology Revenue (Millions) $22$12$33$18$4
Rest of World All other Peri-LOE Products Revenue (Millions) $69$50$76$98$34
Rest of World All other Rare Disease Revenue (Millions) $50$40$38$27$7
Rest of World All other SIP Revenue (Millions) $355$236$426$227$51
Rest of World All other Vaccines Revenue (Millions) $9$7$7-$0$4
Rest of World Alliance Revenue (Millions) $271$198$243$149$27
Rest of World BeneFIX Revenue (Millions) $102$75$120$122$140
Rest of World Biosimilars Revenue (Millions) $12$9$7$1--
Rest of World Celebrex Revenue (Millions) $275$198$283$291$451
Rest of World CentreOne Revenue (Millions) $12$13$25$38$21
Rest of World Chantix/Champix Revenue (Millions) $114$81$133$120$123
Rest of World Consumer Healthcare Revenue (Millions) $303$226$278$274$86
Rest of World Effexor Revenue (Millions) $69$53$52$30$46
Rest of World Enbrel Revenue (Millions) $405$293$424$412$478
Rest of World EpiPen Revenue (Millions) $71$55$55$66$54
Rest of World Essential Health Revenue (Millions) $3,165$2,292$3,348$3,280$1,001
Rest of World Fragmin Revenue (Millions) $77$58$74$80$87
Rest of World Genotropin Revenue (Millions) $160$119$162$155$179
Rest of World Ibrance Revenue (Millions) $25$22$4----
Rest of World Inflammation & Immunology (I&I) Revenue (Millions) $550$401$546$497$148
Rest of World Inflectra/Remsima Revenue (Millions) $12$9$6----
Rest of World Inlyta Revenue (Millions) $86$62$99$83$92
Rest of World Internal Medicine Revenue (Millions) $1,427$1,038$1,410$1,180$562
Rest of World Legacy Established Products (LEP) Revenue (Millions) $1,921$1,414$1,958$2,099$637
Rest of World Lipitor Revenue (Millions) $223$164$235$255$349
Rest of World Medrol Revenue (Millions) $24$18$23$23$33
Rest of World Norvasc Revenue (Millions) $212$153$235$263$363
Rest of World Peri-LOE Products Revenue (Millions) $662$475$706$764$275
Rest of World Premarin family Revenue (Millions) $28$20$28$27$34
Rest of World Prevnar/Prevenar 13 Revenue (Millions) $415$301$435$425$507
Rest of World Pristiq Revenue (Millions) $69$50$71$87$108
Rest of World Rare Disease Revenue (Millions) $389$287$402$379$103
rest of World Refacto AF/Xyntha Revenue (Millions) $54$39$52$44$55
Rest of World Relpax Revenue (Millions) $42$30$45$40$46
Rest of World Revatio Revenue (Millions) $33$23$36$35$46
Rest of World Somavert Revenue (Millions) $19$14$17$16$16
Rest of World Sterile Injectable Pharmaceuticals (SIP) Revenue (Millions) $518$368$555$352$89
Rest of World Sulperazon Revenue (Millions) $13$9$15$16$21
Rest of World Sutent Revenue (Millions) $122$89$122$117$132
Rest of World Total Alliance revenues Revenue (Millions) $287$214$247$151$89
Rest of World Total Lyrica Revenue (Millions) $842$620$809$718$735
Rest of World Total Viagra Revenue (Millions) $70$50$72$76$116
Rest of World Toviaz Revenue (Millions) $91$68$82$66$44
Rest of World Tygacil Revenue (Millions) $8$6$7$7$7
Rest of World Vaccines Revenue (Millions) $425$309$441$426$144
Rest of World Vfend Revenue (Millions) $111$79$125$122$144
Rest of World Viagra EH Revenue (Millions) $37$26$38$40$13
Rest of World Viagra IH Revenue (Millions) $34$25$34$36$12
Rest of World Xalatan/Xalacom Revenue (Millions) $146$105$159$164$198
Rest of World Xalkori Revenue (Millions) $55$41$57$48$62
Rest of World Xanax/Xanax XR Revenue (Millions) $17$12$20$21$28
Rest of World Xeljanz Revenue (Millions) $89$68$59$19$8
Rest of World Zoloft Revenue (Millions) $74$52$90$158$185
Rest of World Zyvox Revenue (Millions) $67$48$78$92$119
Resto of World Oncology Revenue (Millions) $328$244$308$265$74
Total Alliances Revenue (Millions) $2,703$2,112$1,746$1,313$276
Total Lyrica Revenue (Millions) $5,046$3,810$4,966$4,839$5,167
Total Viagra Revenue (Millions) $1,377$996$1,565$1,708$1,685
United States All other Internal Medicine Revenue (Millions) $153$106$177$133$48
United States All other LEP Revenue (Millions) $1,623$1,248$1,650$1,419$399
United States All other Oncology Revenue (Millions) $118$77$157$138$36
United States All other Peri-LOE Products Revenue (Millions) $40$33$42$39$13
United States All other Rare Disease Revenue (Millions) $59$54$43$17$7
United States All other SIP Revenue (Millions) $2,743$1,957$3,042$1,556$198
United States All other Vaccines Revenue (Millions) $90$79$84$18$8
United States Benefix Revenue (Millions) $263$192$301$325$400
United States Biosimilars Revenue (Millions) $78$74$4----
United States BMP2 Revenue (Millions) $274$198$251$233$251
United States Celebrex Revenue (Millions) $143$116$116$145$1,734
United States CentreOne Revenue (Millions) $529$397$478$333$212
United States Chantix/Champix Revenue (Millions) $691$543$597$426$378
United States Consumer Healthcare Revenue (Millions) $1,900$1,339$1,918$1,798$1,697
United States Effexor Revenue (Millions) $80$61$86$95$110
United States EpiPen Revenue (Millions) $262$191$295$272$241
United States Essential Health Revenue (Millions) $8,151$5,808$9,561$7,258$1,892
United States Eucrisa Revenue (Millions) $33$33------
United States Fragmin Revenue (Millions) $22$15$30$25$5
United States Genotropin Revenue (Millions) $101$56$141$162$184
United States Ibrance Revenue (Millions) $2,661$2,048$2,068$718--
United States Inflammation & Immunology Revenue (Millions) $1,134$875$845$468$103
United States Inflectra/Remsima Revenue (Millions) $78$74$4----
United States Inlyta Revenue (Millions) $130$94$161$205$189
United States Innovative Revenue (Millions) $18,172$13,707$16,773$14,446$3,085
United States Internal Medicine Revenue (Millions) $6,858$5,239$6,376$5,704$1,723
United States Legacy Established Products (LEP) Revenue (Millions) $3,445$2,552$3,759$3,574$978
United States Lipitor Revenue (Millions) $176$125$164$161$242
United States Medicine Alliance Revenue (Millions) $1,305$1,041$966$872$187
United States Medrol Revenue (Millions) $309$231$286$220$173
United States Norvasc Revenue (Millions) $37$28$38$36$39
United States Oncology Revenue (Millions) $4,160$3,166$3,166$1,659$251
United States Peri-LOE Products Revenue (Millions) $589$377$930$1,099$636
United States Precedex Revenue (Millions) $103$103------
United States Premarin Family Revenue (Millions) $919$670$957$951$992
United States Prevnar/Prevenar 13 Revenue (Millions) $3,389$2,554$3,645$4,025$2,153
United States Pristiq Revenue (Millions) $246$105$579$553$553
United States Rare Disease Revenue (Millions) $642$456$740$774$246
United States Refacto AF/Xyntha Revenue (Millions) $113$83$122$118$136
United States Relpax Revenue (Millions) $176$126$226$233$245
United States Revatio Revenue (Millions) $115$88$98$65$51
United States Somavert Revenue (Millions) $86$67$77$68$57
United States Sterile Injectable Pharmaceuticals (SIP) Revenue (Millions) $3,231$2,344$3,484$1,910$279
United States Sutent Revenue (Millions) $376$278$390$367$353
United States Total Alliance Revenue (Millions) $1,893$1,487$1,116$889$693
United States Total Lyrica Revenue (Millions) $3,385$2,603$3,138$2,662$2,314
United States Total Viagra Revenue (Millions) $963$688$1,148$1,261$1,140
United States Toviaz Revenue (Millions) $90$63$99$116$133
United States Tygacil Revenue (Millions) $55$39$81$110$112
United States Vaccines Revenue (Millions) $3,479$2,633$3,729$4,043$629
United States Vfend Revenue (Millions) $15$11$32$39$36
United States Xalatan/Xalacom Revenue (Millions) $15$10$18$22$22
United States Xalkori Revenue (Millions) $236$169$251$231$196
United States Xanax/Xanax XR Revenue (Millions) $48$36$49$45$42
United States Xeljanz Revenue (Millions) $1,032$793$805$471$289
United States Xtandi alliance Revenue (Millions) $561$422$139----
United States Zithromax/Zmax Revenue (Millions) $6$5$7$6$12
United States Zoloft Revenue (Millions) $56$41$61$58$55
United States Zyvox Revenue (Millions) $31$24$67$263$680
Untied States All other I&I Revenue (Millions) $70$50$40-$2$8
Worldwide All Other Biosimilars Revenue (Millions) $112$82$126$33--
Worldwide All other I&I Revenue (Millions) $113$78$92$62$12
Worldwide All other Internal Medicine Revenue (Millions) $384$228$517$232$232
Worldwide All other LEP Revenue (Millions) $4,929$3,775$4,812$4,857$1,377
Worldwide All other Oncology Revenue (Millions) $162$101$233$195$118
Worldwide All other Peri-LOE Products Revenue (Millions) $238$176$275$362$140
Worldwide All other Rare Disease Revenue (Millions) $252$218$167$108$50
Worldwide All other SIP Revenue (Millions) $4,151$2,976$4,511$2,563$495
Worldwide All other Vaccines Revenue (Millions) $291$224$266$114$118
Worldwide Benefix Revenue (Millions) $622$453$713$751$856
Worldwide Biosimilars Revenue (Millions) $458$367$318$63--
Worldwide BMP2 Revenue (Millions) $274$198$251$233$251
Worldwide Bosulif Revenue (Millions) $116$116------
Worldwide Celebrex Revenue (Millions) $748$565$732$831$2,700
Worldwide CentreOne Revenue (Millions) $692$514$718$612$451
Worldwide Chantix/Champix Revenue (Millions) $938$727$842$670$647
Worldwide Consumer Healthcare Revenue (Millions) $3,473$2,523$3,407$3,395$3,447
Worldwide Effexor Revenue (Millions) $285$215$277$287$344
Worldwide Enbrel Revenue (Millions) $2,526$1,818$2,908$3,332$3,850
Worldwide EpiPen Revenue (Millions) $340$253$387$339$295
Worldwide Essential Health Revenue (Millions) $21,542$15,640$23,628$22,093$25,149
Worldwide Eucrisa Revenue (Millions) $33$33------
Worldwide Fragmin Revenue (Millions) $300$221$319$335$364
Worldwide FSME/IMMUN-TicoVac Revenue (Millions) $133$121$115$95--
Worldwide Genotropin Revenue (Millions) $529$375$578$616$723
Worldwide Ibrance Revenue (Millions) $3,053$2,410$2,136$723--
Worldwide Inflammation & Immunology Revenue (Millions) $3,885$2,863$3,928$3,917$2,060
Worldwide Inflectra/Remsima Revenue (Millions) $345$284$192$30--
Worldwide Inlyta Revenue (Millions) $354$257$401$430$410
Worldwide Internal Medicine Revenue (Millions) $9,545$7,244$8,858$7,610$5,441
Worldwide Legacy Established Products (LEP) Revenue (Millions) $10,815$7,994$11,193$11,745$3,464
Worldwide Lipitor Revenue (Millions) $1,804$1,340$1,758$1,860$2,062
Worldwide Lyrica EH Revenue (Millions) $607$429$801$1,184$482
Worldwide Lyrica IH Revenue (Millions) $4,439$3,382$4,165$3,655$1,757
Worldwide Medicine Alliance Revenue (Millions) $2,261$1,813$1,609$1,257$464
Worldwide Medrol Revenue (Millions) $471$352$449$402$427
Worldwide Norvasc Revenue (Millions) $933$685$962$992$1,112
Worldwide Oncology Revenue (Millions) $5,909$4,552$4,563$2,955$2,218
Worldwide Peri-LOE Products Revenue (Millions) $3,394$2,398$4,220$5,326$2,077
Worldwide Precedex Revenue (Millions) $243$182$259----
Worldwide Prevnar/Prevenar 13 Revenue (Millions) $5,484$4,068$5,719$6,247$4,464
Worldwide Pristiq Revenue (Millions) $416$231$731$716$737
Worldwide Rare Disease Revenue (Millions) $2,240$1,638$2,369$2,426$1,353
Worldwide Refacto AF/Xyntha Revenue (Millions) $555$409$554$533$630
Worldwide Replax Revenue (Millions) $267$192$323$351$382
Worldwide Revatio Revenue (Millions) $262$190$285$260$275
Worldwide Somavert Revenue (Millions) $241$182$232$218$229
Worldwide Sterile Injectable Pharmaceuticals (SIP) Revenue (Millions) $5,805$4,269$6,018$3,945$865
Worldwide Sulperazon Revenue (Millions) $439$346$396$339$355
Worldwide Sutent Revenue (Millions) $1,077$805$1,095$1,120$1,175
Worldwide Toviaz Revenue (Millions) $254$187$258$266$288
Worldwide Tygacil Revenue (Millions) $262$191$275$305$323
Worldwide Vaccines Revenue (Millions) $5,879$4,384$6,071$6,454$4,480
Worldwide Vfend Revenue (Millions) $437$305$590$681$755
Worldwide Viagra EH Revenue (Millions) $381$284$383$410$122
Worldwide Viagra IH Revenue (Millions) $994$710$1,181$1,297$635
Worldwide Xalatan/Xalacom Revenue (Millions) $331$241$364$399$495
Worldwide Xalkori Revenue (Millions) $588$443$561$487$437
Worldwide Xanax Revenue (Millions) $224$165$221$223$253
Worldwide Xeljanz Revenue (Millions) $1,212$934$927$523$309
Worldwide Xtandi alliance Revenue (Millions) $561$422$139----
Worldwide Zithromax/Zmax Revenue (Millions) $271$202$272$276$313
Worldwide Zoloft Revenue (Millions) $291$215$304$374$422
Worldwide Zyvox Revenue (Millions) $306$220$421$882$1,351